Johnson & Johnson $JNJ Shares Sold by Everett Harris & Co. CA

Everett Harris & Co. CA reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 484,511 shares of the company’s stock after selling 8,388 shares during the period. Johnson & Johnson comprises 0.9% of Everett Harris & Co. CA’s portfolio, making the stock its 23rd largest position. Everett Harris & Co. CA’s holdings in Johnson & Johnson were worth $74,009,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. GFG Capital LLC acquired a new position in shares of Johnson & Johnson in the second quarter worth about $35,000. Stone House Investment Management LLC acquired a new position in shares of Johnson & Johnson in the 1st quarter valued at approximately $47,000. 1248 Management LLC purchased a new position in shares of Johnson & Johnson during the 1st quarter valued at approximately $48,000. Harvest Fund Management Co. Ltd acquired a new stake in shares of Johnson & Johnson during the first quarter worth approximately $52,000. Finally, Pandora Wealth Inc. bought a new stake in shares of Johnson & Johnson in the first quarter worth $65,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.16% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research analysts have commented on the stock. UBS Group increased their price objective on shares of Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a research note on Tuesday, October 14th. Raymond James Financial increased their price target on shares of Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 15th. Daiwa America upgraded Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Morgan Stanley set a $190.00 target price on Johnson & Johnson in a research report on Wednesday, October 15th. Finally, Wells Fargo & Company set a $212.00 price target on Johnson & Johnson and gave the company an “overweight” rating in a research report on Friday, October 3rd. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $199.05.

Johnson & Johnson Stock Up 2.8%

NYSE:JNJ opened at $193.76 on Wednesday. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The stock has a 50 day moving average of $184.79 and a 200-day moving average of $169.31. The firm has a market capitalization of $466.83 billion, a PE ratio of 18.70, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $194.48.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. Analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.